NIVOLUMAB

Information current as at: 1 June 2026

The pharmaceutical company has withdrawn their submission for this medicine prior to the medicine being considered at the PBAC meeting.


PBAC meeting date: July 2021
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Opdivo®
Form and strength:
Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:
Bristol-Myers Squibb Australia Pty Ltd
Condition/indication:
(therapeutic use)
  • Advanced or metastatic non-HER2 positive gastro-oesophageal junction cancer or oesophageal adenocarcinoma
Listing requested:
Please see PSD for more information
Funding program:
Please see PSD for more information
Request authority level:
Please see PSD for more information
PBAC Submission type:
Change to listing (Category 1-2)
Comment:
--
Other PBAC consideration:
--

Progress Details

Submission received for:
July 2021 PBAC meeting
Opportunity for consumer comment:
Not applicable
PBAC meeting:
Not applicable
PBAC outcome published:
Not Applicable (see PBAC Outcomes)
Lodgement of required documentation:
Not applicable
Agreement to listing arrangements:
Not applicable
Government processes:
Not applicable
Medicine listed on the PBS:
Not applicable
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Case ID
a363
Page last updated
31 March 2026
Return to the Medicine Status Listing
v.9.19